Wolfram Brugger

Summary

Affiliation: Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
Country: Germany

Publications

  1. ncbi EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment
    Wolfram Brugger
    Medical Center II, Department of Hematology Oncology, Schwarzwald Baar Clinic, Academic Teaching Hospital University of Freiburg, Villingen Schwenningen, Germany
    Lung Cancer 77:2-8. 2012
  2. ncbi Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support
    W Brugger
    Schwarzwald Baar Clinic Villingen Schwenningen, University of Freiburg, Germany
    Crit Rev Oncol Hematol 72:265-9. 2009
  3. ncbi Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab
    Wolfram Brugger
    Schwarzwald Baar Clinic, Villingen Schwenningen, Teaching Hospital, University of Freiburg, Germany
    Tumori 96:473-7. 2010
  4. ncbi Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer
    Wolfram Brugger
    Schwarzwald Baar Klinikum, Academic Teaching Hospital, University of Freiburg, Voehrenbacher Str 23, Villingen Schwenningen, Germany 78050
    J Clin Oncol 29:4113-20. 2011
  5. ncbi Severe idiopathic erythroblastic synartesis: successful treatment with the anti-CD20 monoclonal antibody rituximab
    Georgios Papakonstantinou
    Medical Center, Department of Hematology Oncology, Schwarzwald Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen Schwenningen, Germany
    Eur J Haematol 84:547-9. 2010

Collaborators

Detail Information

Publications5

  1. ncbi EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment
    Wolfram Brugger
    Medical Center II, Department of Hematology Oncology, Schwarzwald Baar Clinic, Academic Teaching Hospital University of Freiburg, Villingen Schwenningen, Germany
    Lung Cancer 77:2-8. 2012
    ..g. EGFR and MET) and vertical inhibition by combination of small molecules and antibodies, seem to be more promising and will be the prevailing concepts to overcome secondary EGFR-TKI resistance for the near future...
  2. ncbi Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support
    W Brugger
    Schwarzwald Baar Clinic Villingen Schwenningen, University of Freiburg, Germany
    Crit Rev Oncol Hematol 72:265-9. 2009
    ..0 x 10(9)/L versus approximately 25% of those receiving no pegfilgrastim. In conclusion, cycle 1 pegfilgrastim improved recovery from severe neutropenia in elderly breast cancer patients receiving adjuvant FEC100...
  3. ncbi Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab
    Wolfram Brugger
    Schwarzwald Baar Clinic, Villingen Schwenningen, Teaching Hospital, University of Freiburg, Germany
    Tumori 96:473-7. 2010
    ..There are only limited data on the safety and efficacy of panitumumab in patients who experienced severe infusion reactions during cetuximab antibody therapy...
  4. ncbi Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer
    Wolfram Brugger
    Schwarzwald Baar Klinikum, Academic Teaching Hospital, University of Freiburg, Voehrenbacher Str 23, Villingen Schwenningen, Germany 78050
    J Clin Oncol 29:4113-20. 2011
    ..This study included prospective analysis of the prognostic and predictive value of several biomarkers...
  5. ncbi Severe idiopathic erythroblastic synartesis: successful treatment with the anti-CD20 monoclonal antibody rituximab
    Georgios Papakonstantinou
    Medical Center, Department of Hematology Oncology, Schwarzwald Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen Schwenningen, Germany
    Eur J Haematol 84:547-9. 2010
    ..At a follow-up of 30 months after treatment, the patient is still in continuous complete remission without any further treatment, suggesting that rituximab may induce prolonged remissions and eventually cure in this rare disease...